Yetunde Ogunsesan
YOU?
Author Swipe
View article: Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study Open
Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and J…
Characteristics and Prognostic Factors for Patients with Multiple Myeloma Admitted to Intensive Care Unit: A Single-Center Experience Open
We propose a setup consisting of a double-stranded DNA (dsDNA) with s-wave superconductor which can be used to investigate the topological properties. Based on the transport calculations, we find that Majorana zero modes (MZMs) can be form…
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant Open
Background: mRNA vaccines against SARS-CoV-2 have proven to be safe and effective and have been widely administered. Multiple myeloma (MM) is a disease of plasma cells and is known to weaken the host immunity leading to ineffective vaccine…
Corneal toxicity with belantamab mafodotin: Multi‐institutional <span>real‐life</span> experience Open
To the Editor: Since the regulatory approval of monoclonal antibody targeting CD38 antigen in an upfront setting, triple class refractory1 multiple myeloma (MM) is increasingly encountered at an early stage of the disease2 and patients who…
COVID‐19 and acute pancreatitis: A systematic review Open
We aimed to systematically review the relationship between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and acute pancreatitis (AP). The global pandemic of coronavirus disease 2019 (COVID‐19) caused by SARS‐CoV‐2 …
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission Open
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare …
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status Open
Not available.
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma Open
Daratumumab, a CD38-targeting monoclonal antibody, has significantly improved survival rates in multiple myeloma (MM), yet patients who progress on Daratumumab have dismal clinical outcomes with an overall median of less than 10 months. Wh…
282. Epidemiology of Candidemia in Patients with Solid Tumors of the Gastrointestinal Tract Open
Background The Gastrointestinal (GI) tract is considered as an important source of candidemia. Numerous studies indicate that the majority of patients with candidemia and cancer have an underlying solid tumor mostly of the GI tract. Widesp…